CLINICAL TRIAL: TREATMENT WITH (F6-3019) FOR FOCAL GLOMERULOSCLEROSIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 FG-3019治疗将持续2个月，并将在整个2个月治疗期间进行稳态药代动力学研究。药物将每2周给药一次，共给药4次。FG-3019将在2小时内静脉输注给药。输注后，患者将留院观察6小时。在2个月治疗期间，患者将接受总共6次访视。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. FG-3019 treatment will be provided for 2 months and steady state pharmokinetic will be conducted throughout the 2 month treatment period. The drug will be administered every 2 weeks for a total of 4 doses. FG-3019 will be administered as an intravenous infusion over 2 hours. The patient will remain in the hospital for 6 hours following the infusion for observation. The patient will be seen for a total of 6 visits over the 2 month treatment period.